Ep. 78 - SynerFuse® and its innovative approach to spine surgery: better outcomes, improved lives. episode artwork

EPISODE · Apr 30, 2025 · 25 MIN

Ep. 78 - SynerFuse® and its innovative approach to spine surgery: better outcomes, improved lives.

from Capital Fit

I recently had the opportunity to talk with Justin Zenanko, President & CEO of SynerFuse®, which is a cutting-edge, Minnesota-based medical device company innovating the spine industry with its integrated approach to spinal fusion and chronic low back & leg pain. The patented SynerFuse® e-TLIF™ Procedure combines fusion with direct nerve stimulation to address chronic low back and leg pain that enables Ultra Low Energy ™ (ULE™) Therapy that is unaddressed in traditional spinal fusion surgery.SynerFuse® aims to address the fact that as many as 40% of spinal fusion procedures result in chronic, residual pain following a spinal fusion surgery, costing the U.S. healthcare system $20B annually. We discussed:·       How the big strategics are leaving the opportunity for innovation to the small entrepreneurial companies like SynerFuse®.·       How the SynerFuse® integrative technology stimulates the damaged nerves as part of spinal fusion surgery – a world-first approach.·       Anecdotes from the SynerFuse® proof-of-concept study.·       Why Justin has invested his own money into SynerFuse® and his advice to other unconventional entrepreneurs.

I recently had the opportunity to talk with Justin Zenanko, President & CEO of SynerFuse®, which is a cutting-edge, Minnesota-based medical device company innovating the spine industry with its integrated approach to spinal fusion and chronic low back & leg pain. The patented SynerFuse® e-TLIF™ Procedure combines fusion with direct nerve stimulation to address chronic low back and leg pain that enables Ultra Low Energy ™ (ULE™) Therapy that is unaddressed in traditional spinal fusion surgery.SynerFuse® aims to address the fact that as many as 40% of spinal fusion procedures result in chronic, residual pain following a spinal fusion surgery, costing the U.S. healthcare system $20B annually. We discussed:·       How the big strategics are leaving the opportunity for innovation to the small entrepreneurial companies like SynerFuse®.·       How the SynerFuse® integrative technology stimulates the damaged nerves as part of spinal fusion surgery – a world-first approach.·       Anecdotes from the SynerFuse® proof-of-concept study.·       Why Justin has invested his own money into SynerFuse® and his advice to other unconventional entrepreneurs.

NOW PLAYING

Ep. 78 - SynerFuse® and its innovative approach to spine surgery: better outcomes, improved lives.

0:00 25:18

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Capital Fit?

This episode is 25 minutes long.

When was this Capital Fit episode published?

This episode was published on April 30, 2025.

What is this episode about?

I recently had the opportunity to talk with Justin Zenanko, President & CEO of SynerFuse®, which is a cutting-edge, Minnesota-based medical device company innovating the spine industry with its integrated approach to spinal fusion and chronic low...

Can I download this Capital Fit episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!